See more : Bolsa Mexicana de Valores, S.A.B. de C.V. (BOLSAA.MX) Income Statement Analysis – Financial Results
Complete financial analysis of DBV Technologies S.A. (DBVT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of DBV Technologies S.A., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Blockchain Coinvestors Acquisition Corp. I (BCSA) Income Statement Analysis – Financial Results
- PT MNC Energy Investments Tbk (IATA.JK) Income Statement Analysis – Financial Results
- NYLE INC (5618.T) Income Statement Analysis – Financial Results
- Shri Krishna Devcon Limited (SHRIKRISH.BO) Income Statement Analysis – Financial Results
- Confidence Petroleum India Limited (CONFIPET.NS) Income Statement Analysis – Financial Results
DBV Technologies S.A. (DBVT)
About DBV Technologies S.A.
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The milk-induced company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA); Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 15.73M | 4.80M | 5.71M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 240.98K | 332.67K | 333.43K | 297.52K | 213.05K |
| Cost of Revenue | 0.00 | 20.30M | 9.27M | 18.82M | 3.09M | 5.03M | 3.43M | 1.42M | 152.70K | 215.14K | 187.74K | 141.55K | 109.96K |
| Gross Profit | 15.73M | -15.50M | -3.57M | -18.82M | -3.09M | -5.03M | -3.43M | -1.42M | 88.28K | 117.54K | 145.69K | 155.96K | 103.09K |
| Gross Profit Ratio | 100.00% | -322.90% | -62.46% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 36.63% | 35.33% | 43.69% | 52.42% | 48.39% |
| Research & Development | 60.22M | 75.50M | 70.34M | 124.61M | 129.00M | 146.49M | 148.13M | 86.96M | 40.84M | 33.37M | 31.85M | 19.76M | 11.28M |
| General & Administrative | 25.16M | 24.30M | 30.52M | 41.87M | 55.77M | 54.23M | 49.85M | 38.42M | 20.03M | 12.81M | 11.57M | 7.88M | 4.05M |
| Selling & Marketing | -2.28M | 1.60M | 4.39M | 12.12M | 24.07M | 43.97M | 22.27M | 12.45M | 585.76K | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 22.88M | 25.90M | 34.91M | 53.98M | 79.85M | 98.20M | 72.13M | 50.86M | 20.61M | 12.81M | 11.57M | 7.88M | 4.05M |
| Other Expenses | 0.00 | 0.00 | 0.00 | -12.67M | -16.04M | -17.52M | -16.17M | -9.82M | -7.03M | -7.18M | -6.68M | -4.44M | -2.95M |
| Operating Expenses | 92.16M | 101.40M | 105.24M | 165.92M | 192.80M | 227.17M | 204.08M | 128.00M | 54.43M | 39.00M | 36.74M | 23.20M | 12.38M |
| Cost & Expenses | 92.16M | 101.40M | 105.24M | 165.92M | 192.80M | 227.17M | 204.08M | 128.00M | 54.58M | 39.22M | 36.93M | 23.34M | 12.49M |
| Interest Income | 3.78M | 406.29K | 440.79K | 0.00 | 85.15K | 673.86K | 867.09K | 1.67M | 1.21M | 1.15M | 1.23M | 883.09K | 105.44K |
| Interest Expense | 0.00 | 427.00K | 583.77K | 887.89K | 1.79M | 479.76K | 4.68M | 17.65K | 174.18K | 162.96K | 44.59K | 43.01K | 72.00K |
| Depreciation & Amortization | -4.57M | 20.30M | 9.27M | 18.82M | 3.09M | 5.03M | 3.43M | 1.42M | 1.28M | 813.52K | 625.73K | 480.40K | 288.18K |
| EBITDA | -87.46M | -76.68M | -79.77M | -162.74M | -181.37M | -206.16M | -176.90M | -126.29M | -53.62M | -36.00M | -29.56M | -21.68M | -11.88M |
| EBITDA Ratio | -556.11% | -2,012.50% | -1,759.90% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -21,512.88% | -11,099.55% | -10,418.58% | -7,286.80% | -5,575.59% |
| Operating Income | -76.43M | -96.63M | -98.61M | -194.80M | -192.80M | -227.17M | -204.08M | -128.00M | -54.34M | -38.89M | -36.59M | -23.04M | -12.27M |
| Operating Income Ratio | -485.97% | -2,013.15% | -1,727.65% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -22,547.53% | -11,689.15% | -10,974.91% | -7,745.10% | -5,760.35% |
| Total Other Income/Expenses | 3.71M | 431.00K | 8.99M | -24.67M | 9.20M | 15.56M | 19.85M | 1.66M | 1.04M | 986.34K | 1.19M | 840.08K | 33.44K |
| Income Before Tax | -72.72M | -96.20M | -98.19M | -195.69M | -194.51M | -226.98M | -207.90M | -126.35M | -53.30M | -37.90M | -35.41M | -22.20M | -12.24M |
| Income Before Tax Ratio | -462.35% | -2,004.17% | -1,720.22% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -22,116.35% | -11,393.08% | -10,619.61% | -7,462.73% | -5,744.65% |
| Income Tax Expense | 7.00K | 100.00K | -381.00K | -12.26K | 692.67K | 20.50K | 1.41K | 1.67M | 1.21M | 1.15M | 1.23M | 883.08K | 105.44K |
| Net Income | -72.73M | -96.30M | -97.81M | -195.68M | -195.20M | -227.00M | -207.90M | -126.35M | -53.30M | -37.90M | -35.41M | -22.20M | -12.24M |
| Net Income Ratio | -462.40% | -2,006.25% | -1,713.54% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -22,115.85% | -11,393.08% | -10,619.61% | -7,462.73% | -5,744.65% |
| EPS | -2.84 | -4.96 | -7.12 | -14.48 | -21.12 | -31.40 | -33.60 | -20.68 | -9.92 | -9.44 | -10.40 | -7.24 | -3.65 |
| EPS Diluted | -2.84 | -4.96 | -7.12 | -14.48 | -21.12 | -31.40 | -33.60 | -20.68 | -9.92 | -9.44 | -10.40 | -7.24 | -3.65 |
| Weighted Avg Shares Out | 23.78M | 19.35M | 13.77M | 13.52M | 9.25M | 7.23M | 6.18M | 6.11M | 5.37M | 4.02M | 3.40M | 3.07M | 3.35M |
| Weighted Avg Shares Out (Dil) | 23.78M | 19.35M | 13.77M | 13.52M | 9.25M | 7.23M | 6.19M | 6.11M | 5.38M | 4.02M | 3.40M | 3.08M | 3.35M |
DBV Technologies to Report Third Quarter 2023 Financial Results and Business Update
Montrouge, France, October 27, 2023 DBV Technologies to Report Third Quarter 2023 Financial Results and Business Update DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that the Company will host...
DBV Technologies Announces Appointment of Virginie Boucinha as Chief Financial Officer
Montrouge, France, October 16, 2023 DBV Technologies Announces Appointment of Virginie Boucinha as Chief Financial Officer DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced the appointment of Virginie Boucinha as...
DBV Technologies to Participate in Upcoming Investor Conference
Montrouge, France, September 5, 2023 D BV Technologies to Participate in Upcoming Investor Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced the company will participate in the H.C. Wainwright...
DBV Technologies S.A. (DBVT) Q2 2023 Earnings Call Transcript
DBV Technologies S.A. (NASDAQ:DBVT ) Q2 2023 Earnings Call July 31, 2023 5:00 PM ET Company Participants Katie Matthews - Head of Investor Relations Daniel Tassé - Chief Executive Officer Sébastien Robitaille - Chief Financial Officer Pharis Mohideen - Chief...
DBV Technologies Receives Feedback from FDA on Design Elements for Viaskin Peanut Safety Studies and Reports Second Quarter and Half-Year 2023 Financial Results
GlobeNewswire window.initGradientEffect = function () { } document.addEventListener('DOMContentLoaded', function () { const extendedTableZoomElements = document.querySelectorAll('.extended-table-zoom'); if (extendedTableZoomElements && extendedTableZoomElements.length > 0) { window.Stickyfill.add(extendedTableZoomElements); } const socialMediaSideBarContainerElement = document.querySelectorAll('.social-media-side-bar-container'); if (socialMediaSideBarContainerElement && socialMediaSideBarContainerElement.length > 0) { window.Stickyfill.add(socialMediaSideBarContainerElement); } }, false); window.dataLayer...
DBV Technologies to Report First Half 2023 Financial Results and Provide a Corporate Update
Montrouge, France, July 25, 2023 DBV Technologies to Report First Half 202 3 Financial Results and Provide a Corporate Update DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that the...
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
AMF Regulated Information Montrouge, France, July 10, 2023 Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today issued the Half-Year report...
DBV Technologies to Participate in Upcoming Investor Conference
Montrouge, France, June 06, 2023 DB V Technologies to Participate in Upcoming Investor Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced its participation in the Goldman Sachs 44th Annual...
Why Shares of DBV Technologies Jumped Thursday
The company's peanut allergy treatment patch could have a wide impact. DBV Technologies currently has no marketed products.
DBV Technologies to Participate in Upcoming Investor Conference
Montrouge, France, May 9, 2023 D BV Technologies to Participate in Upcoming Investor Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced its participation in the JMP Securities Life Sciences...
Source: https://incomestatements.info
Category: Stock Reports